Core Viewpoint - *ST Changyao has been found to have committed financial fraud for three consecutive years, leading to potential penalties and the risk of forced delisting from the stock market [1][2] Group 1: Financial Misconduct - *ST Changyao received an administrative penalty notice from the China Securities Regulatory Commission for false reporting in annual reports for 2021, 2022, and 2023 [1] - The company inflated its operating revenue by CNY 215 million, CNY 284 million, and CNY 234 million for the years 2021, 2022, and 2023, respectively, which accounted for 9.12%, 17.57%, and 19.51% of the disclosed operating revenue for those years [2] - The total profit was inflated by CNY 56 million, CNY 63 million, and CNY 44 million for the same years, representing 35.62%, 88.23%, and 6.42% of the disclosed profit totals [2] Group 2: Penalties and Consequences - The total proposed penalties amount to CNY 41 million, with *ST Changyao facing a fine of CNY 10 million, and the former actual controller, Luo Ming, facing a fine of CNY 5 million [2] - Other executives may face fines ranging from CNY 1 million to CNY 3 million, with Luo Ming potentially facing a lifetime ban from the securities market and another executive facing a 10-year ban [2] - The company has indicated that its stock may be subject to forced delisting due to significant legal violations [2] Group 3: Business Operations - *ST Changyao's main business operations include pharmaceuticals and photovoltaic products [1]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has imposed severe penalties on Changjiang Pharmaceutical Holdings Co., Ltd. (*ST Changyao) for serious financial fraud, including inflated revenue and profits over three consecutive years, leading to potential delisting due to major violations [1][2]. Group 1: Financial Misconduct - *ST Changyao has been found to have inflated revenue by CNY 215 million, CNY 284 million, and CNY 234 million for the years 2021, 2022, and 2023 respectively, representing 9.12%, 17.57%, and 19.51% of the reported revenue for those years [2]. - The company also inflated total profits by CNY 56.4 million, CNY 63.4 million, and CNY 43.7 million for the same years, accounting for 35.62%, 88.23%, and 6.42% of the reported profits [2]. - In 2022, the company failed to reasonably recognize losses related to a project, resulting in an additional profit inflation of CNY 4.55 million, which was 6.34% of the reported profit for that year [2]. Group 2: Regulatory Actions and Consequences - The CSRC plans to impose a fine of CNY 10 million on *ST Changyao and a total of CNY 31 million on 14 responsible individuals, summing up to a total penalty of CNY 41 million [1]. - The former general manager of *ST Changyao, Luo Ming, will face a lifetime ban from the securities market [1]. - The Shenzhen Stock Exchange will initiate delisting procedures due to the company's serious violations [1][2]. Group 3: Financial Health and Future Risks - As of the end of 2024, the company's net assets attributable to shareholders are projected to be -CNY 433 million, and by the end of the third quarter of 2025, they are expected to be -CNY 643 million [3]. - If the audited net assets for the end of 2025 are negative, the company will face financial delisting risks [3]. - The CSRC is also investigating the auditing firms involved with *ST Changyao, which has had the same auditing firm for five consecutive years, raising concerns about compliance and oversight [3].

又一家上市公司因财务造假走向退市终局。*ST长药因连续三年虚构收入、利润，被证监会重罚，并启 动强制退市程序，成为年内第15家触及重大违法退市红线的公司，数量创历史新高。 监管红线非常明确：财务造假行为持续满三年，就会触及重大违法强制退市。*ST长药正是撞上这 条"高压线"——2021至2023年，其子公司伪造单据虚增收入7.33亿元、利润1.68亿元。 与此同时，监管探照灯也照向中介机构，正核查其是否履职尽责，旨在彻底斩断造假生态链。 *ST长药从立案到下发告知书仅用一个月，监管效率大幅提升。这一切都传递出清晰信号：退市"出 口"正在畅通，财务造假此路不通；任何挑战底线者，都将被坚决清出市场。 （文章来源：21世纪经济报道） 处罚不仅针对公司，更重拳追责到人。14名责任人员被重罚，主导造假的原总经理被终身市场禁入。证 监会对犯罪线索"应移尽移"，行政、民事、刑事"三罚联动"的监管格局已经形成。 ...

Core Viewpoint - Changjiang Pharmaceutical is facing delisting risks due to serious financial fraud allegations, with significant discrepancies in reported revenues and profits over the past three years [1][3]. Group 1: Financial Misconduct - The company reported inflated revenues of 215 million, 284 million, and 234 million yuan for the years 2021, 2022, and 2023, respectively, accounting for 9.12%, 17.57%, and 19.51% of the disclosed revenues for those years [1][4]. - The inflated total profits were 56.4 million, 63.4 million, and 43.7 million yuan for the same years, representing 35.62%, 88.23%, and 6.42% of the disclosed total profits [1][4]. - The company also failed to reasonably recognize losses related to a project, leading to an additional profit inflation of 4.55 million yuan in 2022, which was 6.34% of the disclosed total profits for that year [1]. Group 2: Regulatory Actions - Changjiang Pharmaceutical and 14 responsible individuals have been penalized, with the company fined 10 million yuan and the individuals collectively fined 31 million yuan [2]. - The chairman and former general manager, Luo Ming, was fined 5 million yuan and banned from the securities market for life [2][5]. - The company has been warned that its stock may be subject to delisting due to the continuous financial misreporting over three years [3][6]. Group 3: Financial Health - As of the end of 2024, the company's net assets were reported at -433 million yuan, and by the end of the third quarter of 2025, they had further declined to -643 million yuan [6]. - If the audited net assets for 2025 remain negative, the company will face financial delisting [6]. - The company has initiated pre-restructuring efforts but faces challenges due to ongoing investigations and the risk of major violations leading to delisting [6].

Core Viewpoint - *ST Changyao has been penalized for three consecutive years of financial fraud, leading to a forced delisting process initiated by the Shenzhen Stock Exchange, marking a significant enforcement trend in the capital market against financial misconduct [1][2][14]. Group 1: Company Overview - *ST Changyao, originally established in 2001 and listed in 2014, transitioned from a photovoltaic equipment company to the pharmaceutical sector in 2020 [6]. - The company acquired a 52.75% stake in Hubei Changjiang Star Pharmaceutical Co., which was integrated into its financial statements, leading to its rebranding as Changyao Holdings [6]. Group 2: Financial Fraud Details - From 2021 to 2023, *ST Changyao's subsidiaries inflated revenues by a total of 733 million yuan and profits by 168 million yuan through falsified documents and non-existent sales [7][8]. - The inflated revenues accounted for 9.12%, 17.57%, and 19.51% of the reported revenues for the respective years, while the inflated profits represented 35.62%, 88.23%, and 6.42% of the total profits [7][8]. Group 3: Regulatory Actions - The company has been fined 10 million yuan, and 14 responsible individuals have been collectively fined 31 million yuan, with the former general manager receiving a lifetime ban from the securities market [10][11]. - The regulatory framework has shifted towards a "three-punishment linkage" approach, encompassing administrative, civil, and criminal penalties for financial fraud [10][11]. Group 4: Market Impact - Following the announcement, *ST Changyao's stock fell by 3.92%, with a market capitalization of 510 million yuan, representing a decline of over 90% from its historical peak [3][4]. - The forced delisting of *ST Changyao marks the 15th instance of a company facing mandatory delisting due to significant violations in 2025, reflecting a zero-tolerance policy in the capital market [14][15]. Group 5: Future Implications - The regulatory environment is evolving, with new rules allowing the China Securities Regulatory Commission to directly penalize third-party accomplices involved in financial fraud [2][12]. - Enhanced investor protection mechanisms are being implemented, including measures for compensation from controlling shareholders of companies that face delisting due to fraud [14][15].

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued a notice of administrative penalty against Changjiang Pharmaceutical Holdings Co., Ltd. (*ST Changyao) for suspected false reporting of financial data, revealing that the company inflated revenue and profits for three consecutive years, violating securities laws and regulations [1][5][6]. Group 1: Penalties and Actions - The CSRC plans to impose a fine of 10 million yuan on the company and a total of 31 million yuan in fines on 14 responsible individuals [1][6]. - The former general manager, Luo Ming, will face a lifetime ban from the securities market [1][6]. - The Shenzhen Stock Exchange will initiate delisting procedures due to the company's suspected major violations [1][6]. Group 2: Investigation and Compliance - The CSRC is conducting a simultaneous investigation into the practices of intermediary institutions, with potential penalties for any identified violations [1][6]. - The CSRC will transfer any criminal evidence to the public security authorities in accordance with legal standards [1][6]. Group 3: Stock Performance - As of December 26, the stock price of *ST Changyao was 1.47 yuan, with a market capitalization of 515 million yuan [4][9].

Core Viewpoint - The case of *ST Changyao highlights the severe regulatory environment in the capital market, where continuous financial fraud over three years has led to a lifetime ban for key individuals and an inevitable delisting process for the company [2][3][8]. Group 1: Company Overview - *ST Changyao, originally established in 2001 as Kangyue Technology, transitioned from a photovoltaic equipment manufacturer to a pharmaceutical company in 2020 after acquiring a majority stake in Hubei Changjiang Star Pharmaceutical Co., Ltd [4][5]. - The company reported significant financial irregularities, with a total of 7.33 billion yuan in inflated revenue and 1.68 billion yuan in inflated profits from 2021 to 2023 due to fraudulent activities by its subsidiaries [5][6]. Group 2: Regulatory Actions - The Shenzhen Stock Exchange has initiated a mandatory delisting process for *ST Changyao due to its continuous financial fraud, marking it as the 15th company to face such action in 2023, a record high [2][8]. - The regulatory response includes a fine of 10 million yuan for the company and a total of 31 million yuan in fines for 14 responsible individuals, with the former CEO facing a lifetime ban from the securities market [6][7]. Group 3: Broader Regulatory Trends - The case reflects a broader trend of "zero tolerance" towards financial fraud in the capital market, with new regulations stipulating that companies engaging in financial fraud for three consecutive years will face mandatory delisting [8][9]. - The regulatory framework is evolving to include not only administrative penalties but also civil and criminal liabilities, indicating a comprehensive approach to tackling financial misconduct [6][9]. Group 4: Investor Protection - The China Securities Regulatory Commission (CSRC) is enhancing investor protection mechanisms, requiring major shareholders and actual controllers of delisted companies to take proactive compensation measures [9]. - The implementation of new regulations aims to ensure that even after delisting, companies remain accountable for past fraudulent activities, reinforcing the message that financial misconduct will not be tolerated [9].

Core Viewpoint - The case of *ST Changyao highlights the severe regulatory environment in the capital market, with the company facing a forced delisting due to three consecutive years of financial fraud, marking a record number of such cases in 2023 [1][8]. Group 1: Company Overview - *ST Changyao, originally a photovoltaic equipment company, transitioned to the pharmaceutical sector in 2020, acquiring a 52.75% stake in Hubei Changjiang Star Pharmaceutical Co., which led to its financial reporting issues [4][5]. - The company inflated its revenue by a total of 733 million yuan and profits by 168 million yuan from 2021 to 2023 through fraudulent practices [5][6]. Group 2: Regulatory Actions - The Shenzhen Stock Exchange initiated a forced delisting process against *ST Changyao due to its financial misconduct, which is part of a broader trend of stringent regulatory measures against financial fraud in the capital market [1][8]. - The company was fined 10 million yuan, while 14 responsible individuals were collectively fined 31 million yuan, with the former general manager receiving a lifetime ban from the securities market [6][7]. Group 3: Regulatory Environment - The regulatory framework has evolved to impose harsher penalties on companies and individuals involved in financial fraud, with a new rule stating that companies committing fraud for three consecutive years will face mandatory delisting [8][9]. - The efficiency of regulatory actions has improved, with the investigation and issuance of the administrative penalty notice taking only one month [2][7]. Group 4: Investor Protection - The regulatory body has emphasized investor protection, requiring major shareholders and actual controllers of companies facing delisting to take proactive compensation measures for affected investors [8][9]. - New mechanisms for investor rights protection, such as representative litigation and innovative dispute resolution methods, have been introduced to enhance the efficiency of investor claims [8][9].

经查，*ST长药连续三年虚增收入和利润，违反证券法律法规。证监会拟对上市公司罚款1000万元，对 14名责任人合计罚款3100万元，对公司原总经理罗明采取终身证券市场禁入措施。 证监会表示，*ST长药涉嫌触及重大违法强制退市情形，深交所将依法启动退市程序。 中经记者 孙汝祥 夏欣 北京报道 此外，证监会对中介机构执业情况同步开展核查，一旦发现违法违规情形，将依法予以惩处。对于可能 涉及的犯罪线索，证监会将坚持应移尽移的工作原则，严格按照《刑法》《最高人民检察院 公安部关 于公安机关管辖的刑事案件立案追诉标准的规定（二）》的规定移送公安机关。 证监会网站12月26日公布，近日，证监会对上市公司长江医药控股股份有限公司（以下简称"*ST长药 （维权）"）涉嫌定期报告等财务数据存在虚假记载作出行政处罚事先告知。 （编辑：罗辑 审核：夏欣 校对：颜京宁） ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 证监会严肃查处长药控股严重财务造假案件。 据证监会网站12月26日消息，近日，证监会对上市公司长江医药控股股份有限公司（简称"*ST长药 （维权）"，股票代码：300391）涉嫌定期报告等财务数据存在虚假记载作出行政处罚事先告知。 经查，*ST长药连续三年虚增收入和利润，违反证券法律法规。证监会拟对上市公司罚款1000万元，对 14名责任人合计罚款3100万元，对公司原总经理罗明采取终身证券市场禁入措施。 *ST长药涉嫌触及重大违法强制退市情形，深交所将依法启动退市程序。证监会对中介机构执业情况同 步开展核查，一旦发现违法违规情形，将依法予以惩处。对于可能涉及的犯罪线索，证监会将坚持应移 尽移的工作原则，严格按照《刑法》《最高人民检察院 公安部关于公安机关管辖的刑事案件立案追诉 标准的规定（二）》的规定移送公安机关。 同日，*ST长药发布多则公告。公告显示，公司及相关人员于2025年12月26日收到中国证监会下发的 《行政处罚事先告知书》（以下简称"《告知书》"）。 根据《告知书》认定的事实，公司2021年、2022年、2023年年度报 ...